Madrid, España
La osteoporosis postrasplante causa una importante morbilidad en la creciente población de supervivientes del trasplante hepático. Los fármacos inmunosupresores habitualmente empleados son uno de los principales responsables de la osteoporosis postrasplante. La vitamina D y sus análogos sintéticos podrían ser útiles en el período postrasplante, ya que a sus efectos protectores a nivel óseo se añade su papel inmunomodulador, en particular de la inmunidad mediada por células T, lo que podría permitir no sólo disminuir la dosis de inmunosupresores, sino también colaborar en la prevención de la aparición de rechazo crónico. Liver transplantation has become a fairly common and successful procedure, and post-transplantation osteoporosis is now a usual complication in these patients. Immuno-suppressive therapy has been involved in this setting. Vitamin D and their related analogs may have a role in the post-transplantation therapy, adding the role of immuno-modulator (mainly in T cells) to their already protective one in bone metabolism. This might not only allow for the possibility of reducing immuno-suppressive doses, but also of reducing instances of transplant rejections.
Liver transplantation has become a fairly common and successful procedure, and post-transplantation osteoporosis is now a usual complication in these patients. Immuno-suppressive therapy has been involved in this setting. Vitamin D and their related analogs may have a role in the post-transplantation therapy, adding the role of immuno-modulator (mainly in T cells) to their already protective one in bone metabolism. This might not only allow for the possibility of reducing immuno-suppressive doses, but also of reducing instances of transplant rejections.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados